Challenge of Using Antiplatelet Drugs in Patients With Primary Immune Thrombocytopenia and Recently Implanted Coronary Stents-Splenectomy as a Therapeutic Option

Advances in Pharmacoepidemiology and Drug Safety
doi 10.4172/2167-1052.1000220
Full Text
Abstract

Available in full text

Date
Authors
Publisher

OMICS Publishing Group

Related search

A Blinded Study of Bone Marrow Examinations in Patients With Primary Immune Thrombocytopenia

European Journal of Haematology
MedicineHematology
2012English

Therapeutic Effectiveness and Safety of Implanted Drug Eluting Stents

Heart
Cardiovascular MedicineCardiology
2012English

Switching Thrombopoietin Receptor Agonist Treatments in Patients With Primary Immune Thrombocytopenia

Therapeutic Advances in Hematology
Hematology
2019English

Recurrent Coronary Thrombus in a Patient With Chronic Immune Thrombocytopenia With Treatment Using Eltrombopag

Case Reports in Cardiology
Cardiovascular MedicineCardiology
2019English

Gastroenterological Perspectives on Acute Cardiac Care — The Management of Patients With Implanted Coronary Stents Following an Acute Coronary Syndrome

Journal Of Cardiovascular Emergencies
2018English

Case of Feline Idiopathic Immune-Mediated Thrombocytopenia Effectively Treated With Cyclophosphamide After Splenectomy

Journal of the Japan Veterinary Medical Association
2014English

Variability in Antiplatelet Drugs' Response in Indian Patients Undergoing Percutaneous Coronary Intervention and Outcome Modification by Tailored Antiplatelet Therapy

Journal of Cardiology & Cardiovascular Therapy
2018English

Gemcitabine Re-Challenge in Metastatic Soft Tissue Sarcomas: A Therapeutic Option for Selected Patients

Anticancer Research
MedicineCancer ResearchOncology
2018English

Current Management of Primary Immune Thrombocytopenia

Advances in Therapy
MedicinePharmacology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy